RESOLVING THE NEUROBIOLOGICAL MECHANISMS OF ANXIETY DISORDERS – BRAIN IMAGING SUB-STUDY

Phase 1

• Conditions: Social Anxiety disorder; MedDRA version: 19.0Level: PTClassification code 10041242Term: Social anxiety disorderSystem Organ Class: 10037175 - Psychiatric disorders; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2014-005366-30-FI
• Lead Sponsor: niversity of Helsinki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-29
• Last Update Posted: 12 September 2016

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Social anxiety disorder, age 18-65
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion criteria are: borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder; lifetime substance dependence, last-year substance abuse, last month over 24/16 standard doses of alcohol/week; last month use of any illicit substance or last 3 month use of cannabis; unstable somatic illness; antidepressant medication use in last 4 months and use of antipsychotics, mood stabilizers, systemic corticosteroids, ß-blockers or daytime benzodiazepines (a small dose of =10mg zolpidem once daily is permissible).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified